Logo image of 1MRNA.MI

MODERNA INC (1MRNA.MI) Stock Fundamental Analysis

BIT:1MRNA - Euronext Milan - US60770K1079 - Common Stock - Currency: EUR

31.98  +3.51 (+12.33%)

Fundamental Rating

4

1MRNA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 72 industry peers in the Biotechnology industry. While 1MRNA seems to be doing ok healthwise, there are quite some concerns on its profitability. 1MRNA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

1MRNA had negative earnings in the past year.
In the past year 1MRNA has reported a negative cash flow from operations.
In multiple years 1MRNA reported negative net income over the last 5 years.
In multiple years 1MRNA reported negative operating cash flow during the last 5 years.
1MRNA.MI Yearly Net Income VS EBIT VS OCF VS FCF1MRNA.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B

1.2 Ratios

The Return On Assets of 1MRNA (-25.18%) is comparable to the rest of the industry.
1MRNA's Return On Equity of -32.67% is fine compared to the rest of the industry. 1MRNA outperforms 61.11% of its industry peers.
Industry RankSector Rank
ROA -25.18%
ROE -32.67%
ROIC N/A
ROA(3y)-6.14%
ROA(5y)4.17%
ROE(3y)-7.66%
ROE(5y)6.83%
ROIC(3y)N/A
ROIC(5y)N/A
1MRNA.MI Yearly ROA, ROE, ROIC1MRNA.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

1.3 Margins

1MRNA's Gross Margin of 68.70% is fine compared to the rest of the industry. 1MRNA outperforms 68.06% of its industry peers.
1MRNA's Gross Margin has declined in the last couple of years.
1MRNA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.55%
GM growth 5YN/A
1MRNA.MI Yearly Profit, Operating, Gross Margins1MRNA.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

6

2. Health

2.1 Basic Checks

1MRNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for 1MRNA has been increased compared to 1 year ago.
Compared to 5 years ago, 1MRNA has more shares outstanding
Compared to 1 year ago, 1MRNA has an improved debt to assets ratio.
1MRNA.MI Yearly Shares Outstanding1MRNA.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
1MRNA.MI Yearly Total Debt VS Total Assets1MRNA.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.2 Solvency

1MRNA has an Altman-Z score of 3.39. This indicates that 1MRNA is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.39, 1MRNA belongs to the top of the industry, outperforming 80.56% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that 1MRNA is not too dependend on debt financing.
1MRNA's Debt to Equity ratio of 0.00 is amongst the best of the industry. 1MRNA outperforms 90.28% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.39
ROIC/WACCN/A
WACC9.17%
1MRNA.MI Yearly LT Debt VS Equity VS FCF1MRNA.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B

2.3 Liquidity

A Current Ratio of 3.67 indicates that 1MRNA has no problem at all paying its short term obligations.
With a decent Current ratio value of 3.67, 1MRNA is doing good in the industry, outperforming 73.61% of the companies in the same industry.
1MRNA has a Quick Ratio of 3.62. This indicates that 1MRNA is financially healthy and has no problem in meeting its short term obligations.
1MRNA's Quick ratio of 3.62 is fine compared to the rest of the industry. 1MRNA outperforms 73.61% of its industry peers.
Industry RankSector Rank
Current Ratio 3.67
Quick Ratio 3.62
1MRNA.MI Yearly Current Assets VS Current Liabilites1MRNA.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 25.22% over the past year.
Looking at the last year, 1MRNA shows a very negative growth in Revenue. The Revenue has decreased by -52.75% in the last year.
The Revenue has been growing by 122.01% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)25.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-629.09%
Revenue 1Y (TTM)-52.75%
Revenue growth 3Y-44.04%
Revenue growth 5Y122.01%
Sales Q2Q%-65.64%

3.2 Future

The Earnings Per Share is expected to grow by 18.22% on average over the next years. This is quite good.
The Revenue is expected to grow by 22.61% on average over the next years. This is a very strong growth
EPS Next Y-6.83%
EPS Next 2Y8.61%
EPS Next 3Y11.69%
EPS Next 5Y18.22%
Revenue Next Year-31.86%
Revenue Next 2Y-8.21%
Revenue Next 3Y2.35%
Revenue Next 5Y22.61%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
1MRNA.MI Yearly Revenue VS Estimates1MRNA.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5B 10B 15B
1MRNA.MI Yearly EPS VS Estimates1MRNA.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10 20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for 1MRNA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for 1MRNA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
1MRNA.MI Price Earnings VS Forward Price Earnings1MRNA.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
1MRNA.MI Per share data1MRNA.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.61%
EPS Next 3Y11.69%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for 1MRNA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MODERNA INC

BIT:1MRNA (3/6/2025, 7:00:00 PM)

31.98

+3.51 (+12.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-14 2025-02-14/bmo
Earnings (Next)04-30 2025-04-30/bmo
Inst Owners73.88%
Inst Owner ChangeN/A
Ins Owners5.45%
Ins Owner ChangeN/A
Market Cap12.34B
Analysts64.38
Price Target53.15 (66.2%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)47.64%
Min EPS beat(2)-6.26%
Max EPS beat(2)101.54%
EPS beat(4)3
Avg EPS beat(4)28.71%
Min EPS beat(4)-6.26%
Max EPS beat(4)101.54%
EPS beat(8)6
Avg EPS beat(8)1.03%
EPS beat(12)8
Avg EPS beat(12)2.8%
EPS beat(16)11
Avg EPS beat(16)3.24%
Revenue beat(2)2
Avg Revenue beat(2)23.24%
Min Revenue beat(2)0.45%
Max Revenue beat(2)46.04%
Revenue beat(4)4
Avg Revenue beat(4)48.29%
Min Revenue beat(4)0.45%
Max Revenue beat(4)78.74%
Revenue beat(8)8
Avg Revenue beat(8)36.49%
Revenue beat(12)10
Avg Revenue beat(12)27.34%
Revenue beat(16)12
Avg Revenue beat(16)19.08%
PT rev (1m)-22.06%
PT rev (3m)-30.78%
EPS NQ rev (1m)-8.77%
EPS NQ rev (3m)-3.55%
EPS NY rev (1m)-8.17%
EPS NY rev (3m)-9.26%
Revenue NQ rev (1m)-35.17%
Revenue NQ rev (3m)-57.11%
Revenue NY rev (1m)-10.41%
Revenue NY rev (3m)-27.46%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.14
P/FCF N/A
P/OCF N/A
P/B 1.23
P/tB 1.24
EV/EBITDA N/A
EPS(TTM)-8.55
EYN/A
EPS(NY)-9.13
Fwd EYN/A
FCF(TTM)-9.68
FCFYN/A
OCF(TTM)-7.17
OCFYN/A
SpS7.73
BVpS26.02
TBVpS25.8
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.18%
ROE -32.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.7%
FCFM N/A
ROA(3y)-6.14%
ROA(5y)4.17%
ROE(3y)-7.66%
ROE(5y)6.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.55%
GM growth 5YN/A
F-Score5
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 556.09%
Cap/Sales 32.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.67
Quick Ratio 3.62
Altman-Z 3.39
F-Score5
WACC9.17%
ROIC/WACCN/A
Cap/Depr(3y)261.63%
Cap/Depr(5y)224.68%
Cap/Sales(3y)14.96%
Cap/Sales(5y)10.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-629.09%
EPS Next Y-6.83%
EPS Next 2Y8.61%
EPS Next 3Y11.69%
EPS Next 5Y18.22%
Revenue 1Y (TTM)-52.75%
Revenue growth 3Y-44.04%
Revenue growth 5Y122.01%
Sales Q2Q%-65.64%
Revenue Next Year-31.86%
Revenue Next 2Y-8.21%
Revenue Next 3Y2.35%
Revenue Next 5Y22.61%
EBIT growth 1Y11.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year10.98%
EBIT Next 3Y20.6%
EBIT Next 5Y19.47%
FCF growth 1Y-6.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3.66%
OCF growth 3YN/A
OCF growth 5YN/A